KDR and hepatocellular carcinoma: Moreover, toripalimab (anti-PD-1) plus anlotinib (a VEGF-R2 inhibitor) showed promising results as first-line therapy for patients with unresectable HCC with an ORR of 29%, median PFS of 11 months, and median OS of 18.2 months [37].